NASDAQ:STRO Sutro Biopharma Q3 2025 Earnings Report $0.80 -0.01 (-0.63%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Sutro Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.39Beat/MissN/AOne Year Ago EPSN/ASutro Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASutro Biopharma Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Sutro Biopharma Earnings HeadlinesSutro Biopharma announces restructuring, workforce reduction of about 33%September 29, 2025 | msn.comSutro Biopharma stock jumps after restructuring to extend cash runwaySeptember 29, 2025 | za.investing.comDARPA Set to Trigger New Boom: Buy These 3 StocksBy the end of this month, DARPA — the government agency that invented the internet — is expected to make a major quantum computing announcement that could send three little-known quantum stocks soaring.October 15 at 2:00 AM | Brownstone Research (Ad)Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key MilestonesSeptember 29, 2025 | globenewswire.comSutro Biopharma price target lowered to $4 from $7 at JefferiesSeptember 9, 2025 | msn.comVaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal DiseaseSeptember 3, 2025 | quiverquant.comQSee More Sutro Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sutro Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your email. Email Address About Sutro BiopharmaSutro Biopharma (NASDAQ:STRO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas. With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.View Sutro Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings CSX (10/16/2025)Interactive Brokers Group (10/16/2025)Bank of New York Mellon (10/16/2025)American Noble Gas (10/16/2025)Marsh & McLennan Companies (10/16/2025)Charles Schwab (10/16/2025)Travelers Companies (10/16/2025)Taiwan Semiconductor Manufacturing (10/16/2025)U.S. Bancorp (10/16/2025)American Express (10/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
